TY - JOUR
T1 - The Contribution of Endothelial Activation and Injury to End-Organ Toxicity following Allogeneic Hematopoietic Stem Cell Transplantation
AU - Cooke, Kenneth R.
AU - Jannin, Anne
AU - Ho, Vincent
N1 - Funding Information:
Dr. Cooke is an Amy Strelzer-Manasevit Scholar of the National Marrow Donor Program, a Leukemia and Lymphoma Society Scholar in Clinical Research, and the recipient of a Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund.
PY - 2008/1
Y1 - 2008/1
N2 - Over the last 25 years, allogeneic hematopoietic stem cell transplantation (HSCT) has been used increasingly as a curative treatment option for patients with hematologic and neoplastic diseases. Despite major advances in transplant immunology and improvements in supportive and critical care medicine, HSCT is still plagued by several life-threatening complications. As such, the establishment of effective therapeutic options for these complications will be crucial as increasing numbers of high-risk transplants are performed each year. This brief review will discuss the contribution of vascular endothelial cell activation and injury to inflammation and end-organ toxicity that occurs following allogeneic HSCT, and will highlight translational research efforts that have paved the way to the development of novel strategies to treat and prevent disease. Finally, we will discuss in detail the clinical manifestations and challenges encompassed by the syndrome of thrombotic microangiopathy following HSCT.
AB - Over the last 25 years, allogeneic hematopoietic stem cell transplantation (HSCT) has been used increasingly as a curative treatment option for patients with hematologic and neoplastic diseases. Despite major advances in transplant immunology and improvements in supportive and critical care medicine, HSCT is still plagued by several life-threatening complications. As such, the establishment of effective therapeutic options for these complications will be crucial as increasing numbers of high-risk transplants are performed each year. This brief review will discuss the contribution of vascular endothelial cell activation and injury to inflammation and end-organ toxicity that occurs following allogeneic HSCT, and will highlight translational research efforts that have paved the way to the development of novel strategies to treat and prevent disease. Finally, we will discuss in detail the clinical manifestations and challenges encompassed by the syndrome of thrombotic microangiopathy following HSCT.
KW - Cytokines
KW - Endothelial cell
KW - Graft-versus-host disease
KW - Hematopoietic stem cell transplantation
KW - Idiopathic pneumonia syndrome
KW - Inflammation
KW - Microvasculature
KW - Thrombotic microangiopathy
KW - Tumor necrosis factor-alpha
KW - Veno-occlusive disease
UR - http://www.scopus.com/inward/record.url?scp=37449023779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37449023779&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2007.10.008
DO - 10.1016/j.bbmt.2007.10.008
M3 - Article
C2 - 18162218
AN - SCOPUS:37449023779
SN - 1083-8791
VL - 14
SP - 23
EP - 32
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1 SUPPL.
ER -